Diabetes, cancer, and metformin: connections of metabolism and cell proliferation
暂无分享,去创建一个
[1] L. Hennighausen,et al. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis. , 2002, Cancer research.
[2] R. Ozaki,et al. Low HDL Cholesterol, Metformin Use, and Cancer Risk in Type 2 Diabetes , 2011, Diabetes Care.
[3] Massimiliano Cazzaniga,et al. Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysis , 2010, Cancer Prevention Research.
[4] B. Martín-Castillo,et al. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells , 2011, Breast Cancer Research and Treatment.
[5] Damien Laporte,et al. Metabolic status rather than cell cycle signals control quiescence entry and exit , 2011, The Journal of cell biology.
[6] R. N. Bergman,et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study , 1992, The Lancet.
[7] E. Giovannucci,et al. A Meta-analysis of Diabetes Mellitus and the Risk of Prostate Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.
[8] Xilin Yang,et al. Associations of Hyperglycemia and Insulin Usage With the Risk of Cancer in Type 2 Diabetes: The Hong Kong Diabetes Registry , 2010, Diabetes.
[9] E. Gottlieb,et al. Mitochondria in cancer: not just innocent bystanders. , 2009, Seminars in cancer biology.
[10] Yongxian Zhuang,et al. Cell cycle arrest in Metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1 , 2008, Journal of molecular signaling.
[11] Douglas Hanahan,et al. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.
[12] S. Nagamatsu,et al. Expression of Facilitative Glucose Transporter Isoforms in Human Brain Tumors , 1993, Journal of neurochemistry.
[13] N. Legros,et al. Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. , 1972, Cancer research.
[14] A. Tsirigos,et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer , 2011, Cell cycle.
[15] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[16] A. Levine,et al. The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes , 2010, Science.
[17] Han Liu,et al. High glucose promotes cell proliferation and enhances GDNF and RET expression in pancreatic cancer cells , 2010, Molecular and Cellular Biochemistry.
[18] Matthias Egger,et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis , 2004, The Lancet.
[19] A. Wolff,et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. , 2008, JAMA.
[20] C. la Vecchia,et al. Metabolic syndrome and endometrial cancer risk. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] W. R. Bruce,et al. Hyperinsulinemia, but not other factors associated with insulin resistance, acutely enhances colorectal epithelial proliferation in vivo. , 2006, Endocrinology.
[22] C. Mantzoros,et al. Type 2 diabetes mellitus and medications for type 2 diabetes mellitus are associated with risk for and mortality from cancer in a German primary care cohort. , 2011, Metabolism: clinical and experimental.
[23] K. Yasuda,et al. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression. , 2002, Biochimica et biophysica acta.
[24] D. Berrigan,et al. Accelerated tumor formation in a fatless mouse with type 2 diabetes and inflammation. , 2006, Cancer research.
[25] M. Cifuentes,et al. Insulin regulates GLUT1‐mediated glucose transport in MG‐63 human osteosarcoma cells , 2011, Journal of cellular physiology.
[26] D. Yee,et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. , 2007, Cancer research.
[27] S. Larsson,et al. Diabetes mellitus and risk of bladder cancer: a meta-analysis , 2006, Diabetologia.
[28] J. Best,et al. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer , 2005, Journal of cellular physiology.
[29] M. Pollak,et al. Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. , 2010, Endocrine-related cancer.
[30] F. Huang,et al. Insulin receptor (IR) pathway hyperactivity in IGF-IR null cells and suppression of downstream growth signaling using the dual IGF-IR/IR inhibitor, BMS-754807. , 2010, Endocrinology.
[31] S. Majumdar,et al. Increased Cancer-Related Mortality for Patients With Type 2 Diabetes Who Use Sulfonylureas or Insulin , 2006, Diabetes Care.
[32] D. Burstein,et al. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. , 1997, Thyroid : official journal of the American Thyroid Association.
[33] N. Nader,et al. Sex hormone-binding globulin gene expression in the liver: Drugs and the metabolic syndrome , 2010, Molecular and Cellular Endocrinology.
[34] D. Leroith,et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. , 2008, Cancer research.
[35] S. Koujak,et al. Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer , 2010, Molecular Cancer Therapeutics.
[36] Bethany B Barone,et al. Diabetes mellitus and breast cancer outcomes: a systematic review and meta-analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] M. Wong,et al. Associations between adipokines and obesity-related cancer. , 2011, Frontiers in bioscience.
[38] Anna Marie Mulligan,et al. Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer , 2007, Breast Cancer Research and Treatment.
[39] K. Takata,et al. Immunohistochemical localization of glucose transporters in human renal cell carcinoma. , 1995, The Journal of urology.
[40] Ming-Rong Wang,et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth , 2011, Proceedings of the National Academy of Sciences.
[41] Han You,et al. Coordination and communication between the p53 and IGF-1-AKT-TOR signal transduction pathways. , 2006, Genes & development.
[42] Edward Giovannucci,et al. Diabetes and Cancer , 2010, Diabetes Care.
[43] E. Simpson,et al. Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase , 2010, Breast Cancer Research and Treatment.
[44] B. Hoffman,et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] H. Friess,et al. Human insulin receptor and insulin signaling proteins in hepatic disease. , 1999, The Journal of surgical research.
[46] A. Tannenbaum,et al. The influence of the degree of caloric restriction on the formation of skin tumors and hepatomas in mice. , 1949, Cancer research.
[47] Karl Pearson,et al. On the Correlation of Death‐Rates , 1910 .
[48] R. Brand,et al. Elevated insulin receptor content in human breast cancer. , 1990, The Journal of clinical investigation.
[49] I. G. Fantus,et al. Insulin-lowering effects of metformin in women with early breast cancer. , 2008, Clinical breast cancer.
[50] T. Oguri,et al. Differential Expression of Facilitative Glucose Transporter (GLUT) Genes in Primary Lung Cancers and Their Liver Metastases , 1999, Japanese journal of cancer research : Gann.
[51] M. Rigoulet,et al. Dimethylbiguanide Inhibits Cell Respiration via an Indirect Effect Targeted on the Respiratory Chain Complex I* , 2000, The Journal of Biological Chemistry.
[52] Kazutomo Inoue,et al. Over-expression of facilitative glucose transporter genes in human cancer. , 1990, Biochemical and biophysical research communications.
[53] M. Woodward,et al. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies , 2005, British Journal of Cancer.
[54] D. Albanes,et al. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. , 2009, Journal of the National Cancer Institute.
[55] S. Tu,et al. Thiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[56] R A Jungmann,et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[57] Nobuyuki Tanaka,et al. p53 regulates glucose metabolism through an IKK-NF-κB pathway and inhibits cell transformation , 2008, Nature Cell Biology.
[58] G A Colditz,et al. Dual effects of weight and weight gain on breast cancer risk. , 1997, JAMA.
[59] G. Eibl,et al. Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. , 2009, Cancer research.
[60] M. Taiji,et al. Metformin suppresses glucose-6-phosphatase expression by a complex I inhibition and AMPK activation-independent mechanism. , 2009, Biochemical and biophysical research communications.
[61] F. Clavel-Chapelon,et al. Serum levels of IGF‐I, IGFBP‐3 and colorectal cancer risk: results from the EPIC cohort, plus a meta‐analysis of prospective studies , 2010, International journal of cancer.
[62] S. Baer,et al. Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia. , 1997, Journal of the American Academy of Dermatology.
[63] the Scottish Diabetes Research Network Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group , 2009, Diabetologia.
[64] N. Hamilton,et al. Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and -β via the IGF-1 and the insulin receptors in breast cancer cells , 2011, Growth factors.
[65] Hongbing Shen,et al. Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies , 2009, European Journal of Human Genetics.
[66] S. Bonovas,et al. Diabetes mellitus and risk of prostate cancer: a meta-analysis , 2004, Diabetologia.
[67] D. Balzi,et al. Metformin and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients , 2010, Diabetes Care.
[68] M. Stampfer,et al. A prospective study of plasma C-peptide and colorectal cancer risk in men. , 2004, Journal of the National Cancer Institute.
[69] S. Lau,et al. In vitro metformin anti-neoplastic activity in epithelial ovarian cancer. , 2008, Gynecologic oncology.
[70] M. Armoni,et al. The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression , 2004, Cancer Research.
[71] B. Martín-Castillo,et al. Metformin regulates breast cancer stem cello ntogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status , 2010, Cell cycle.
[72] A. Ferrara,et al. Diabetes and risk of bladder cancer , 2011, Cancer.
[73] A STATISTICAL STUDY IN CANCER DEATH-RATES , 1910 .
[74] R. Brown,et al. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. , 1995, Anticancer research.
[75] G. Hortobagyi,et al. Impact of diabetes mellitus on complications and outcomes of adjuvant chemotherapy in older patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] M. Kaminski,et al. A Pathobiological Role of the Insulin Receptor in Chronic Lymphocytic Leukemia , 2011, Clinical Cancer Research.
[77] C. Mantzoros,et al. Circulating Insulin and C-Peptide Levels and Risk of Breast Cancer among Predominately Premenopausal Women , 2007, Cancer Epidemiology Biomarkers & Prevention.
[78] A. Buchs,et al. Incidence of malignancies in patients with diabetes mellitus and correlation with treatment modalities in a large Israeli health maintenance organization: a historical cohort study. , 2011, Metabolism: clinical and experimental.
[79] J. Everhart,et al. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. , 1995, JAMA.
[80] M. Mathieu,et al. Insulin receptor expression and clinical outcome in node-negative breast cancer. , 1997, Proceedings of the Association of American Physicians.
[81] J. Kaufman,et al. Estrogen receptor alpha (ERα) and insulin‐like growth factor I receptor (IGF‐IR) cross‐talk in the gonadotropic αT3‐1 cell line , 2007 .
[82] S. Satoh,et al. Expression of facilitative glucose transporter isoforms in lung carcinomas: its relation to histologic type, differentiation grade, and tumor stage. , 1998, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.
[83] Eyal Gottlieb,et al. TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.
[84] B. Viollet,et al. Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. , 2010, The Journal of clinical investigation.
[85] D. Sabatini,et al. Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.
[86] P. Pour,et al. Diabetes mellitus: a risk factor for pancreatic cancer? , 2005, Langenbeck's Archives of Surgery.
[87] M. Pollak,et al. Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells , 2010, Breast Cancer Research and Treatment.
[88] The Statistical Study of Cancer , 1926 .
[89] Thomas E Rohan,et al. Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. , 2009, Journal of the National Cancer Institute.
[90] I. Ben-Sahra,et al. Metformin, independent of AMPK, induces mTOR inhibition and cell-cycle arrest through REDD1. , 2011, Cancer research.
[91] S. Krähenbühl,et al. Long-Term Metformin Use Is Associated With Decreased Risk of Breast Cancer , 2010, Diabetes Care.
[92] Dario R Alessi,et al. Metformin and reduced risk of cancer in diabetic patients , 2005, BMJ : British Medical Journal.
[93] Kevin Struhl,et al. Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types. , 2011, Cancer research.
[94] Sterling C. Johnson,et al. Caloric Restriction Delays Disease Onset and Mortality in Rhesus Monkeys , 2009, Science.
[95] H. El‐Serag,et al. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[96] L. Pusztai,et al. Evidence for biological effects of metformin in operable breast cancer: a pre-operative, window-of-opportunity, randomized trial , 2011, Breast Cancer Research and Treatment.
[97] D. Esposito,et al. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro. , 2002, The Journal of clinical endocrinology and metabolism.
[98] R. Deberardinis,et al. Q's next: the diverse functions of glutamine in metabolism, cell biology and cancer , 2010, Oncogene.
[99] J. Johnson,et al. Intensive glycaemic control and cancer risk in type 2 diabetes: a meta-analysis of major trials , 2010, Diabetologia.
[100] P. Eyer. Influence of nutritional factors on prevalence of diabetes, J.M. Kalbfleisch, K.M. West, in: Diabetes, 20. (Feb. 1971), 99 , 1972 .
[101] S. Larsson,et al. Diabetes mellitus and incidence of kidney cancer: a meta-analysis of cohort studies , 2011, Diabetologia.
[102] P. Donnan,et al. New Users of Metformin Are at Low Risk of Incident Cancer , 2009, Diabetes Care.
[103] F. Ovalle. Metformin Associated With Lower Cancer Mortality in Type 2 Diabetes: ZODIAC-16 , 2010 .
[104] K. Takata,et al. Investigative Urology: Immunohistochemical Localization of Glucose Transporters in Human Renal Cell Carcinoma , 1995 .
[105] S. Larsson,et al. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.
[106] P. Sen,et al. Involvement of the Akt/PKB signaling pathway with disease processes , 2003, Molecular and Cellular Biochemistry.
[107] C. la Vecchia,et al. Metabolic syndrome and the risk of breast cancer in postmenopausal women. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.
[108] V. Basevi. Standards of Medical Care in Diabetes—2011 , 2011, Diabetes Care.
[109] M. S. Kirkman,et al. Comment on: American Diabetes Association. Standards of Medical Care in Diabetes—2011. Diabetes Care 2011;34(Suppl. 1):S11–S61 , 2011 .
[110] K. M. West,et al. Influence of Nutritional Factors on Prevalence of Diabetes , 1971, Diabetes.
[111] E. Gale,et al. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes , 2009, Diabetologia.
[112] C. Mantzoros,et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis , 2007, Diabetologia.
[113] S. Hankinson,et al. A Prospective Study of C-Peptide, Insulin-like Growth Factor-I, Insulin-like Growth Factor Binding Protein-1, and the Risk of Colorectal Cancer in Women , 2005, Cancer Epidemiology Biomarkers & Prevention.
[114] Nahum Sonenberg,et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. , 2006, Cancer research.
[115] T. Yoshikawa,et al. Glucose uptake in the human gastric cancer cell line, MKN28, is increased by insulin stimulation. , 1999, Cancer letters.
[116] A. Avogaro,et al. Glycated hemoglobin and antidiabetic strategies as risk factors for hepatocellular carcinoma. , 2010, World journal of gastroenterology.
[117] D. Ayer,et al. An extended Myc network contributes to glucose homeostasis in cancer and diabetes. , 2011, Frontiers in bioscience.
[118] R. Baxter,et al. Association between Serum Insulin, Serum Somatomedin and Liver Receptors for Human Growth Hormone in Streptozotocin Diabetes , 1980, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[119] Michael J Thun,et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. , 2003, The New England journal of medicine.
[120] A. Medline,et al. Insulin promotion of colon tumors in rats. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[121] P. Smolewski. Recent developments in targeting the mammalian target of rapamycin (mTOR) kinase pathway , 2006, Anti-cancer drugs.
[122] S. Perkins,et al. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. , 2010, Carcinogenesis.
[123] M. Thun,et al. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. , 2004, American journal of epidemiology.
[124] I. Ben-Sahra,et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level , 2008, Oncogene.
[125] E. Barrett-Connor,et al. Insulin-like growth factor-I and cancer mortality in older men. , 2010, The Journal of clinical endocrinology and metabolism.
[126] Funda Meric-Bernstam,et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[127] E. Rofstad,et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. , 2000, Cancer research.
[128] François G. Meyer,et al. Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies , 2008, Annals of Internal Medicine.
[129] Alicja Wolk,et al. Diabetes mellitus and risk of breast cancer: A meta‐analysis , 2007, International journal of cancer.
[130] J. Kieswich,et al. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. , 2010, The Journal of endocrinology.
[131] Chi V. Dang,et al. The interplay between MYC and HIF in cancer , 2008, Nature Reviews Cancer.
[132] B. Turk,et al. AMPK phosphorylation of raptor mediates a metabolic checkpoint. , 2008, Molecular cell.
[133] J. French,et al. Dietary restriction reduces insulin-like growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53-deficient mice. , 1997, Cancer research.
[134] A. Mancuso,et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase , 2011, Nature Cell Biology.
[135] Kevin Struhl,et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. , 2009, Cancer research.
[136] D. Tindall,et al. FOXOs, cancer and regulation of apoptosis , 2008, Oncogene.
[137] D. Leroith,et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. , 2010, Cancer research.
[138] X. Ding,et al. Physiological Concentrations of Insulin Augment Pancreatic Cancer Cell Proliferation and Glucose Utilization By Activating MAP Kinase, PI3 Kinase and Enhancing GLUT-1 Expression , 2000, Pancreas.
[139] Robert H. Bell,et al. Insulin receptor expression by human prostate cancers , 2009, The Prostate.